PMID- 35712467
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a 
      Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes.
PG  - 878098
LID - 10.3389/fonc.2022.878098 [doi]
LID - 878098
AB  - To further emphasize the clinical-genetic features and prognosis of CDKN2A/B 
      deletions in childhood acute lymphoblastic leukemia (ALL), we retrospectively 
      analyzed 819 consecutive B-ALL patients treated with the Chinese Children's 
      Cancer Group ALL-2015 (CCCG-ALL-2015) protocol, and fluorescence in situ 
      hybridization (FISH) analysis on CDKN2A/B deletion was available for 599 
      patients. The prevalence of CDKN2A/B gene deletions was 20.2% (121/599) of B-ALL. 
      CDKN2A/B deletions were significantly associated with older age, higher leukocyte 
      counts, a higher percentage of hepatosplenomegaly, and a higher frequency of 
      BCR-ABL (p < 0.05). Those patients achieved similar minimal residual disease 
      (MRD) clearance and complete remission compared to patients without CDKN2A/B 
      deletion. The CDKN2A/B deletions were correlated with inferior outcomes, 
      including a 3-year event-free survival (EFS) rate (69.8 +/- 4.6 vs. 89.2 +/- 1.6%, p 
      = 0.000) and a 3-year overall survival (OS) rate (89.4% +/- 2.9% vs. 94.7% +/- 1.1%, 
      p = 0.037). In multivariable analysis, CDKN2A/B deletion was still an independent 
      prognostic factor for EFS in total cohorts (p < 0.05). We also detected a 
      multiplicative interaction between CDKN2A/B deletions and TP53 deletion on dismal 
      prognosis (p-interaction < 0.05). In conclusion, CDKN2A/B deletion is associated 
      with distinct characteristics and serves as a poor prognostic factor in pediatric 
      ALL, especially in TP53 deletion carriers.
CI  - Copyright (c) 2022 Feng, Guo, Yang, Zou, Zhang, Chen, Zhang, Zhu and Chen.
FAU - Feng, Jing
AU  - Feng J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Guo, Ye
AU  - Guo Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Yang, Wenyu
AU  - Yang W
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Zou, Yao
AU  - Zou Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Chen, Yumei
AU  - Chen Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Zhang, Yingchi
AU  - Zhang Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Zhu, Xiaofan
AU  - Zhu X
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Chen, Xiaojuan
AU  - Chen X
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20220524
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9195293
OTO - NOTNLM
OT  - CDKN2A/B
OT  - TP53
OT  - fluorescence in situ hybridization
OT  - pediatric acute lymphoblastic leukemia
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/18 06:00
MHDA- 2022/06/18 06:01
PMCR- 2022/01/01
CRDT- 2022/06/17 02:42
PHST- 2022/02/17 00:00 [received]
PHST- 2022/04/14 00:00 [accepted]
PHST- 2022/06/17 02:42 [entrez]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/06/18 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.878098 [doi]
PST - epublish
SO  - Front Oncol. 2022 May 24;12:878098. doi: 10.3389/fonc.2022.878098. eCollection 
      2022.